No advantage of continuous vs intermittent meropenem in critically ill patients – the MERCY trial

1. The MERCY trial revealed that continuous infusion of meropenem does not confer a significant advantage over intermittent administration in reducing mortality and preventing new antibiotic-resistant bacteria in patients with either septic shock or sepsis. 2. This randomized control trial provides contrary evidence to previous systematic reviews and meta-analyses that found better outcomes with continuous

Related Keywords

Russia ,Italy ,Croatia ,Kazakhstan , ,Intermittent Administration Of Meropenem ,Rating Level ,Continuous Infusion ,Intermittent Administration ,Critically Ill Patients ,Simplified Acute Physiology Score ,Antibiotic ,Continuous ,Intermittent ,Mercy ,Meropenem ,Sepsis ,Septic Shock ,Infectious Disease ,